NCT07579663Not yet recruitingNot Applicable
Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment: a Multicenter Randomized Controlled Study
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University0 sites142 target enrollmentStarted: May 5, 2026Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 142
Study Overview
Brief Summary
The purpose of this study is to compare the efficacy and safety of an individualized two-stage calcium supplementation method versus a conventional commercial RCA-CRRT module in RCA-CRRT for patients with citrate metabolism disorders.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •A. Aged 18 to 80 years, inclusive, male or female; B. Diagnosed with acute kidney injury or chronic kidney disease stage 5, and assessed by a physician as requiring continuous renal replacement therapy (CRRT); C. Citrate metabolism disorder, including liver failure (acute liver failure, acute-on-chronic liver failure, or decompensated cirrhosis), and/or microcirculation disorder (mean arterial pressure <65 mmHg requiring vasopressor therapy and lactate ≥2 mmol/L); D. The investigator determines that the patient can have a stable vascular access established (the access must be capable of providing a constant and effective blood flow rate >150 ml/min); E. The study participant (subject) and their legal guardian are able to understand the study purpose and provide written informed consent.
Exclusion Criteria
- •A. Received regional citrate anticoagulation therapy within the previous 72 hours; B. Expected to require additional non-protocol calcium supplementation during CRRT due to disease-related needs; C. Requiring arterial-venous reversal of the extracorporeal circuit during CRRT due to poor flow; D. Requiring concurrent peritoneal dialysis during the trial period; E. Participated in or is currently participating in another clinical trial within 1 month prior to the date of signing the informed consent form; F. Expected survival time less than 72 hours; G. Any other conditions that, in the investigator's judgment, make the patient unsuitable for participation in the clinical trial.
Investigators
Ding Feng
Professor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Similar Trials
Not yet recruiting
Not Applicable
Comparison of Citrate and Heparin Anticoagulation During Postdilution HemodiafiltrationRenal FailureNCT07618858University Medical Centre Ljubljana20
Not yet recruiting
Not Applicable
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary EmbolismPulmonary EmbolismVenous ThromboembolismNCT07603700Nanjing First Hospital, Nanjing Medical University1,300
Terminated
Phase 3
Customized Citrate Anticoagulation versus No Anticoagulant in Continuous Venovenous Hemofiltration in Critically ill patients with Acute Kidney InjuryFilter clotting in patients with acute kidney injury requiring continuous venovenous hemofiltrationCVVHregional citrate anticoagulationcustomized citrate-based replacement fluidcitrate accumulationbleedingTCTR20210924001Faculty of Medicine Siriraj Hospital , Mahidol University ,Thailand78
Recruiting
Phase 3
Blood thinners after transcatheter implantation of a new heart valve in patients with aortic stenosisAortic stenosis2023-510211-20-00Oslo University Hospital HF360
Active, not recruiting
Not Applicable
Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.NCT07358416Petrovsky National Research Centre of Surgery500